All In Biotech

Drug Trial Radar · NCT07734116

A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

A Multicenter, Open-label, Uncontrolled Phase I/II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma, and to Evaluate the Tolerability in Pediatric Patients.

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Nov 30, 2029

Study completion Feb 29, 2032

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma, and to evaluate the tolerability in pediatric patients. The objective of this study is to explore the tolerability, safety, efficacy, and pharmacokinetics of ONO-4538HSC in patients with pediatric malignant solid tumors. The other objective is to exploratively investigate the efficacy and safety of ONO-4538HSC in patients with epithelioid sarcoma.

Conditions

  • Pediatric Malignant Solid Tumor and Epithelioid Sarcoma

Interventions

  • ONO-4538HSCDrug

    ONO-4538HSC will be administered subcutaneously once every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events meeting protocol-defined criteria for a DLTTime frame: 28 days
  2. Serious adverse eventsTime frame: UP to 100 days after the last dose
  3. Adverse eventsTime frame: UP to 100 days after the last dose
  4. Response rate (central assessment)Time frame: Through study completion, an average of 6 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Chiba University Hospital

    Chiba, Chiba, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Not yet recruiting

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan · Recruiting

  • Hiroshima University Hospital

    Hiroshima, Hiroshima, Japan · Not yet recruiting

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, Japan · Not yet recruiting

  • Yokohama City University Hospital

    Yokohama, Kanagawa, Japan · Not yet recruiting

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan · Recruiting

  • Mie University Hospital

    Tsu, Mie-ken, Japan · Not yet recruiting

  • Tohoku University Hospital

    Sendai, Miyagi, Japan · Not yet recruiting

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan · Not yet recruiting

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan · Recruiting

  • Kindai University Hospital

    Sakai, Osaka, Japan · Not yet recruiting

  • Shizuoka Cancer Center

    Sunto-gun, Shizuoka, Japan · Not yet recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.